Atypical antipsychotic drugs: Theories of mechanism of action

Atypical Antipsychotics: From Bench to Bedside

Volumn , Issue , 2004, Pages 1-15

  Filippino, Scott ^a   Csernansky, John G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84872282982     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (77)

1. Laborit H, Huguenard P. L’hibernation artificielle par moyens pharmacodynamiques et physiques. Presse Med 1951; 59:1329.
2. Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20:140-144.
3. Anden NE, Roos BE, Werdinius B. Effects of chlorpromazine, haloperidol, and reserpine on the levels of phenolic acids in rabbit corpus striatum. Life Sci 1964; 3:149.
4. Anden NE, Butcher SG, Corrodi H, Fuxe K, Ungerstedt U. Receptor activity and turnover of dopamine and noradrenaline after neuroleptics. Eur J Pharmacol 1970; 11:303-314.
5. Hippius H. A historical perspective of clozapine. J Clin Psychiatry 1999; 60 (suppl 12):22-23.
6. Shen WW. A history of antipsychotic drug development. Compr Psychiatry 1999; 40:407-414.
7. Idanpaan-Heikkila J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with clozapine. Eur J Clin Pharmacol 1977; 11:193-198.
8. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796.
9. Meltzer HY. Action of atypical antipsychotics. Am J Psychiatry 2002; 159: 153-154.
10. Sulpizio A, Fowler PJ, Macko E. Antagonism of fenfluramine-induced hyperthermia: a measure of central serotonin inhibition. Life Sci 1978; 22:1439-1446.
11. Altar CA, Wasley AM, Neale RF, Stone GA. Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 1986 16:517-525.
12. Costall B, Fortune DH, Naylor RJ, Mardsen CD, Pycock C. Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 1975; 14:859-868.
13. Costall B, Naylor RJ. Neuroleptic interaction with the serotoninergic-dopaminergic mechanisms in the nucleus accumbens. J Pharm Pharmacol 1978; 30:257-259.
14. Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N. 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 1990; 13:500-506.
15. Ceulemans DL, Gelders YG, Hoppenbrouwers ML, Reyntjens AJ, Janssen PA. Effect of serotonin antagonism in schizophrenia: a pilot study with setoperone. Psychopharmacology (Berl) 1985; 85:329-332.
16. Meltzer HY. Commentary on “Clinical studies on the mechanism of action of clozapine; the dopamine-serotonin hypothesis of schizophrenia in Psychopharmacology 1989"; 99:S18-S27; Psychopharmacology (Berl) 2002; 163:1-3.
17. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3:1607-1619.
18. Meltzer HY. Clozapine: mechanism of action in relation to its clinical advantages. In: Kales A, Stefanos CN, Talbott JA (eds) Recent advances in Schizophrenia. New York: Springer-Verlag, 1990.
19. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamineserotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989; 99 (Suppl):S18-S27.
20. Miczek KA. Landmark publications in Psychopharmacology: the first 40 years. Psychopharmacology (Berl) 2001; 153:399-401.
21. Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 1989; 251:238-246.
22. Parent A. Human Neuroanatomy, 9th edn, Baltimore: Williams and Wilkins, 1995.
23. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain-IV. Autoradiographic mapping of serotonin-2 receptors. Neuroscience 1987; 21:123-139.
24. Ugedo L, Grenhoff J, Svensson TH. Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology (Berl) 1989; 98:45-50.
25. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148:1474-1486.
26. Knable MB, Weinberger DR. Dopamine, the prefrontal cortex and schizophrenia. J Psychopharmacol 1997; 11:123-131.
27. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996; 124:57-73.
28. Saller CF, Salama AI. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology (Berl) 1993; 112:285-292.
29. Meltzer HY. Atypical antipsychotics. In: Psychopharmacology, The Fourth Generation of Progress Online Edition. American College of Neuropsychopharmacology 2000. www.acnp.org/g4.
30. Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27-38.
31. Trichard C, Paillere-Martinot ML, Attar-Levy D, Recassens C, Monnet F, Martinot JL. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry 1998; 155:505-508.
32. Kapur S, Seeman P. Author reply to Meltzer HY: Action of atypical antipsychotics. Am J Psychiatry 2002; 159:153-155.
33. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514-520.
34. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49:538-544.
35. Nordstrom AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, Uppfeldt G. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33:227-235.
36. Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezawas L, Barnas C, Tauscher-Wisniewski S, Brucke T, Kasper S. In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) 1999; 141:175-181.
37. Knable MB, Heinz A, Raedler T, Weinberger DR. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels. Psychiatry Res 1997; 75:91-101.
38. Bench CJ, Lammertsma AA, Dolan RJ, Grasby PM, Warrington SJ, Gunn K, Cuddigan M, Turton DJ, Osman S, Frackowiak RS. Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88, 059-01: a study using positron emission tomography and 11C-raclopride. Psychopharmacology (Berl) 1993; 112:308-314.
39. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57:553-559.
40. Tauscher-Wisniewski S, Kapur S, Tauscher J, Jones C, Daskalakis ZJ, Papatheodorou G, Epstein I, Christensen BK, Zipursky RB. Quetiapine: an effective antipsychotic in first-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. J Clin Psychiatry 2002; 63:992-997.
41. Suhara T, Okauchi T, Sudo Y, Takano A, Kawabe K, Maeda J, Kapur S. Clozapine can induce high dopamine D(2) receptor occupancy in vivo. Psychopharmacology (Berl) 2002; 160:107-112.
42. Kapur S, McClelland RA, VanderSpek SC, Wadenberg ML, Baker G, Nobrega J, Zipursky RB, Seeman P. Increasing D2 affinity results in the loss of clozapine’s atypical antipsychotic action. Neuroreport 2002; 13:831-835.
43. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry 2001; 158:360-369.
44. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 2000; 25:161-166.
45. Kapur S, Remington G. Dopamine D(2) receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 2001; 50:873-883.
46. Lefkowitz RJ, Cotecchia S, Samama P, Costa T. Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol Sci 1993; 14:303-307.
47. Strange PG. Agonism and inverse agonism at dopamine D2-like receptors. Clin Exp Pharmacol Physiol Suppl 1999; 26:S3-S9.
48. Strange PG. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 2001; 53:119-133.
49. Rauser L, Savage JE, Meltzer HY, Roth BL. Inverse agonist actions of typical and atypical antipsychotic drugs at the human 5-hydroxytryptamine(2C) receptor. J Pharmacol Exp Ther 2001; 299:83-89.
50. Douglas CJ. Apomorphine as a hypnotic. NY Med J 1900; 71:376.
51. Kehr W, Carlsson A, Lindqvist M, Magnusson T, Atack C. Evidence for a receptormediated feedback control of striatal tyrosine hydroxylase activity. J Pharm Pharmacol 1972; 24:744-747.
52. Tamminga CA, Schaffer MH, Smith RC, Davis JM. Schizophrenic symptoms improve with apomorphine. Science 1978; 200:567-568.
53. Tamminga CA, Chase TN. Bromocriptine and CF 25-397 in the treatment of tardive dyskinesia. Arch Neurol 1980; 37:204-205.
54. Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL. Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry 1986; 43:398-402.
55. Tamminga CA. Partial dopamine agonists in the treatment of psychosis. J Neural Transm 2002; 109:411-20.
56. Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A. Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm Gen Sect 1992; 88:165-175.
57. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA. Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-npropylpiperidine (preclamol) in schizophrenia. Biol Psychiatry 1998; 43:2-11.
58. Kiuchi K, Hirata Y, Minami M, Nagatsu T. Effect of 7-(3-[4-(2, 3-dimethylphenyl) piperazinyl] propoxy)-2(1H)-quinolinone (OPC-4392), a newly synthesized agonist for presynaptic dopamine D2 receptor, on tyrosine hydroxylation in rat striatal slices. Life Sci 1988; 42:343-349.
59. Kikuchi T, Tottori K, Uwahodo Y, Hirose T, Miwa T, Oshiro Y, Morita S. 7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995; 274:329-336.
60. Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002; 27:248-259.
61. Jackson DM, Mohell N, Bengtsson A, Malmberg A. Why does clozapine stimulate the motor activity of reserpine-pretreated rats when combined with a dopamine D1 receptor agonist? Eur J Pharmacol 1995; 282:137-144.
62. Ninan I, Kulkarni SK. Partial agonistic action of clozapine at dopamine D2 receptors in dopamine depleted animals. Psychopharmacology (Berl) 1998; 135:311-317.
63. Ichikawa J, Meltzer HY. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res 2000; 858:252-263.
64. Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O’Laughlin IA, Meltzer HY. 5-HT (2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 2001; 76:1521-1531.
65. Kalkman HO. Antischizophrenic activity independent of dopamine D2 blockade. Expert Opin Ther Targets 2002; 6:571-582.
66. Carfagno ML, Hoskins LA, Pinto ME, Yeh JC, Raffa RB. Indirect modulation of dopamine D2 receptors as potential pharmacotherapy for schizophrenia: II. Glutamate antagonists. Ann Pharmacother 2000; 34:788-797.
67. Sulzer D, Joyce MP, Lin L, Geldwert D, Haber SN, Hattori T, Rayport S. Dopamine neurons make glutamatergic synapses in vitro. J Neurosci 1998 18:4588-4602.
68. Deakin FW, Simpson MD, Slater P, Hellewell JS. Familial and developmental abnormalities of front lobe function and neurochemistry in schizophrenia. J Psychopharmacol 1997; 11:133-142.
69. Javitt DC. Glycine modulators in schizophrenia. Curr Opin Investig Drugs 2002; 3:1067-1072.
70. Vandenberg RJ, Aubrey KR. Glycine transport inhibitors as potential antipsychotic drugs. Expert Opin Ther Targets 2001; 5:507-518.
71. Rao PA, Pickar D, Gejman PV, Ram A, Gershon ES, Gelernter J. Allelic variation in the D4 dopamine receptor (DRD4) gene does not predict response to clozapine. Arch Gen Psychiatry 1994; 51:912-917.
72. Wilson JM, Sanyal S, Van Tol HH. Dopamine D2 and D4 receptor ligands: relation to antipsychotic action. Eur J Pharmacol 1998; 351:273-286.
73. Nemeroff CB. Neurotensin: perchance an endogenous neuroleptic? Biol Psychiatry 1980; 15:283-302.
74. Kinkead B, Binder EB, Nemeroff CB. Does neurotensin mediate the effects of antipsychotic drugs? Biol Psychiatry 1999; 46:340-351.
75. Breslin NA, Suddath RL, Bissette G, Nemeroff CB, Lowrimore P, Weinberger DR. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Schizophr Res 1994; 12:35-41.
76. Binder EB, Kinkead B, Owens MJ, Nemeroff CB. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol Psychiatry 2001; 50:856-872.
77. Kinkead B, Nemeroff CB. Neurotensin: an endogenous antipsychotic? Curr Opin Pharmacol 2002; 2:99-103.